QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lorrain, J. Articles by O'Connor, S. E. Search for Related Content PubMed PubMed Citation Articles by Lorrain, J. Articles by O'Connor, S. E.

CARDIOVASCULAR

Antithrombotic Properties of SSR182289A, a New, Orally Active Thrombin Inhibitor

Sanofi-Synthélabo Research, Cardiovascular-Thrombosis Research Department, Chilly-Mazarin and Toulouse, France

N-[3-[[[(1S)-4-(5-Amino-2-pyridinyl)-1-[[4-difluoromethylene)-1-piperidinyl]carbonyl]butyl]amino]sulfonyl][1,1'-biphenyl]-2-yl]acetamide hydrochloride (SSR182289A) is a novel, potent, and selective thrombin inhibitor. We have examined the antithrombotic properties of SSR182289A administered by i.v. and p.o. routes in several different animal thrombosis models in comparison with reference antithrombotic agents. Oral administration of SSR182289A produced dose-related antithrombotic effects in the following models; rat venous thrombosis (ED₅₀ 0.9 mg/kg p.o.), rat silk thread arterio-venous (AV) shunt (ED₅₀ 3.8 mg/kg p.o.), rat thromboplastin-induced AV shunt (ED₅₀ 3.1 mg/kg p.o.), rat carotid artery thrombosis (ED₂₀₀ 5.9 mg/kg p.o.), and rabbit venous thrombosis (ED₅₀ 7.5 mg/kg p.o.). Administered as an i.v. bolus, SSR182289A showed antithrombotic activity in the above models with ED₅₀/ED₂₀₀ values in the range of 0.2 to 1.9 mg/kg i.v. SSR182289A increased rat tail transection bleeding time at doses 10 mg/kg p.o. In the rat thromboplastin-induced AV shunt model, SSR182289A 10 mg/kg p.o. produced marked antithrombotic effects at 30, 60, 120, and 240 min after administration. Hence, SSR182289A demonstrates potent oral antithrombotic properties in animal venous, AV-shunt, and arterial thrombosis models.

Address correspondence to: Dr. S. E. O'Connor, Cardiovascular-Thrombosis Department, Sanofi-Synthélabo Research, 1 Avenue Pierre Brossolette, 91385 Chilly-Mazarin Cedex, France. E-mail: stephen-eric.o'connor{at}sanofi-synthelabo.com

This article has been cited by other articles:

				P. W. Bedard, V. Clerin, N. Sushkova, B. Tchernychev, T. Antrilli, C. Resmini, J. C. Keith Jr., J. K. Hennan, N. Kaila, S. DeBernardo, et al. Characterization of the Novel P-Selectin Inhibitor PSI-697 [2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] Quinoline-4-carboxylic acid] in Vitro and in Rodent Models of Vascular Inflammation and Thrombosis J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 497 - 506. [Abstract] [Full Text] [PDF]

				J G. Duplantier, L Dubuisson, N Senant, G Freyburger, I Laurendeau, J-M Herbert, A Desmouliere, and J Rosenbaum A role for thrombin in liver fibrosis Gut, November 1, 2004; 53(11): 1682 - 1687. [Abstract] [Full Text] [PDF]